Ira M. Klein, MD, MBA, FACP

Articles

Grappling With the Fallout of Genetic Testing, in Oncology and Beyond

January 29, 2014

Moving beyond the topic, Companion Diagnostics in Targeted Treatment, the panel took on the unregulated nature of testing in the wake of the June 2013 US Supreme Court ruling against Myriad Genetics, which ended the company's BRCA testing monopoly.

Discussion 6: Next‐Generation Genetic Sequencing in Oncology: Ready for Prime Time?

December 28, 2013

Mr Klein leads another discussion with Michael Kolodjiez, MD, Lee N. Newcomer, MD, MHA, John L. Fox, MD, MHA, and Jerry Conway. The panel responds to whether there are gaps in targeted gene analyses. They also discuss other issues including bioinformatics, and how payers, providers, and pharmacists might collaborate on improving care through genetic sequencing.

Discussion 5: Companion Diagnostics in Targeted Treatments

December 28, 2013

Dr Klein moderates this discussion, including co-editor in chief of The American Journal of Pharmacy Benefits Dr Jan Berger. The panel addresses a variety of topics as they relate to companion diagnostics in targeted treatments. Panelists respond to issues such as who should take responsibility in genetic counseling to ensure that patients have the best experience possible-whether it be in person or telephonic. Other topics covered in this discussion include appropriate consumerism in this space, the employer's role in genetic counseling, and how medical professionals are being trained or educated about these processes.

Discussion 3: Challenges and Opportunities for Quality Measures in Oncology

December 28, 2013

Dr Klein begins the panel discussion by asking participants to name one of their biggest challenges. Dr Newcomer responds that time and the fact that there are not enough PhDs are challenging. Ms Torda suggests that standardized data and data collection remains difficult. Dr Scanlon says it's the nimbleness of structuring data.

Discussion 2: Implications of Healthcare Reform: 'No†Will Be Heard

December 28, 2013

Implications of Healthcare Reform: 'No' Will Be Heard is led by Cliff Goodman, PhD, in a panel discussion featuring A. Mark Fendrick, MD, co-editor in chief of The American Journal of Managed Care, John L. Fox, MD, MHA, and Ira M. Klein, MD, MBA, FACP. The panelists determine what it means when a patient says no.